Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials

BACKGROUND: Many clinical trials have assessed the effect and safety of monoclonal antibodies (MAbs) in combination with proteasome inhibitors or immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma (MM). The treatment outcomes of comparing different MAbs in combinati...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Wu, Wu, Xia, Liu, Xiaoyan, Zheng, Xue, Deng, Jili, Gong, Yuping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419924/
https://www.ncbi.nlm.nih.gov/pubmed/34488679
http://dx.doi.org/10.1186/s12885-021-08588-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419924/
https://www.ncbi.nlm.nih.gov/pubmed/34488679
http://dx.doi.org/10.1186/s12885-021-08588-9

Ejemplares similares